ID CO9_RAT Reviewed; 554 AA.
AC Q62930; Q62957;
DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT 01-NOV-1996, sequence version 1.
DT 04-NOV-2026, entry version 153.
DE RecName: Full=Complement component C9;
DE Flags: Precursor;
GN Name=C9;
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, TISSUE
RP SPECIFICITY, AND DEVELOPMENTAL STAGE.
RC STRAIN=Sprague-Dawley;
RX PubMed=9212048; DOI=10.1203/00006450-199707000-00020;
RA Lassiter H.A., Walz B.M., Wilson J.L., Jung E., Calisi C.R.,
RA Goldsmith L.J., Wilson R.A., Morgan B.P., Feldhoff R.C.;
RT "The administration of complement component C9 enhances the survival of
RT neonatal rats with Escherichia coli sepsis.";
RL Pediatr. Res. 42:128-136(1997).
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA].
RC STRAIN=Sprague-Dawley;
RA Hinchliffe S.J., Van den Berg C.W., Rushmere N.K., Morgan B.P.;
RT "Cloning of rat C9: consequences for homologous restriction of
RT complement.";
RL Submitted (MAR-1996) to the EMBL/GenBank/DDBJ databases.
CC -!- FUNCTION: Pore-forming component of the membrane attack complex (MAC),
CC a multiprotein complex activated by the complement cascade, which
CC inserts into a target cell membrane and forms a pore, leading to target
CC cell membrane rupture and cell lysis (PubMed:9212048). The MAC is
CC initiated by proteolytic cleavage of C5 into complement C5b in response
CC to the classical, alternative, lectin and GZMK complement pathways (By
CC similarity). The complement pathways consist in a cascade of proteins
CC that leads to phagocytosis and breakdown of pathogens and signaling
CC that strengthens the adaptive immune system (By similarity).
CC Constitutes the pore-forming subunit of the MAC complex: during MAC
CC assembly, C9 associates with the C5b8 intermediate complex, and
CC polymerizes to complete the pore (By similarity).
CC {ECO:0000250|UniProtKB:P02748, ECO:0000269|PubMed:9212048}.
CC -!- ACTIVITY REGULATION: Membrane attack complex (MAC) assembly is
CC inhibited by CD59, thereby protecting self-cells from damage during
CC complement activation. CD59 acts by preventing incorporation of the
CC multiple copies of C9 required for complete formation of the osmolytic
CC pore. MAC assembly is also inhibited by clusterin (CLU) chaperones that
CC inhibit polymerization of C9. {ECO:0000250|UniProtKB:P02748}.
CC -!- SUBUNIT: Homooligomer; about 20 C9 chains oligomerize to give rise to a
CC huge beta-barrel that forms a 100 Angstrom diameter pore in target
CC membranes. Component of the membrane attack complex (MAC), composed of
CC complement C5b, C6, C7, C8A, C8B, C8G and multiple copies of the pore-
CC forming subunit C9. {ECO:0000250|UniProtKB:P02748}.
CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:9212048}. Target
CC cell membrane {ECO:0000269|PubMed:9212048}; Multi-pass membrane protein
CC {ECO:0000250|UniProtKB:P02748}. Note=Secreted as soluble monomer.
CC Oligomerizes at target membranes, forming a pre-pore. A conformation
CC change then leads to the formation of a 100 Angstrom diameter pore.
CC {ECO:0000250|UniProtKB:P02748}.
CC -!- TISSUE SPECIFICITY: Detected in blood serum (at protein level).
CC {ECO:0000269|PubMed:9212048}.
CC -!- DEVELOPMENTAL STAGE: Detected at low levels in neonate blood serum.
CC Levels increase throughout the first three weeks after birth.
CC {ECO:0000269|PubMed:9212048}.
CC -!- PTM: Phosphorylation sites are present in the extracellular medium.
CC {ECO:0000250|UniProtKB:P02748}.
CC -!- SIMILARITY: Belongs to the complement C6/C7/C8/C9 family.
CC {ECO:0000305}.
CC -!- SEQUENCE CAUTION:
CC Sequence=AAA96528.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; U49071; AAB38023.1; -; mRNA.
DR EMBL; U52948; AAA96528.1; ALT_INIT; mRNA.
DR RefSeq; NP_476487.2; NM_057146.2.
DR AlphaFoldDB; Q62930; -.
DR SMR; Q62930; -.
DR BioGRID; 250734; 1.
DR FunCoup; Q62930; 136.
DR STRING; 10116.ENSRNOP00000018545; -.
DR GlyCosmos; Q62930; 3 sites, No reported glycans.
DR GlyGen; Q62930; 4 sites.
DR iPTMnet; Q62930; -.
DR PhosphoSitePlus; Q62930; -.
DR SwissPalm; Q62930; -.
DR PaxDb; 10116-ENSRNOP00000018545; -.
DR GeneID; 117512; -.
DR KEGG; rno:117512; -.
DR AGR; RGD:620319; -.
DR CTD; 735; -.
DR RGD; 620319; C9.
DR eggNOG; ENOG502QWHM; Eukaryota.
DR InParanoid; Q62930; -.
DR OMA; AAEFQCE; -.
DR OrthoDB; 10037824at2759; -.
DR Reactome; R-RNO-977606; Regulation of Complement cascade.
DR PRO; PR:Q62930; -.
DR Proteomes; UP000002494; Unplaced.
DR GO; GO:0005576; C:extracellular region; EXP:UniProtKB.
DR GO; GO:0005579; C:membrane attack complex; ISS:UniProtKB.
DR GO; GO:0044218; C:other organism cell membrane; ISS:UniProtKB.
DR GO; GO:0005886; C:plasma membrane; ISO:RGD.
DR GO; GO:0001906; P:cell killing; ISO:RGD.
DR GO; GO:0006956; P:complement activation; ISS:UniProtKB.
DR GO; GO:0160257; P:complement activation, GZMK pathway; ISS:UniProtKB.
DR GO; GO:0045087; P:innate immune response; ISO:RGD.
DR GO; GO:0031640; P:killing of cells of another organism; ISO:RGD.
DR GO; GO:0051260; P:protein homooligomerization; ISO:RGD.
DR GO; GO:0055085; P:transmembrane transport; IEA:GOC.
DR CDD; cd00112; LDLa; 1.
DR FunFam; 2.10.25.10:FF:000766; Complement component C9; 1.
DR FunFam; 2.20.100.10:FF:000089; Complement component C9; 1.
DR FunFam; 4.10.400.10:FF:000213; Complement component C9; 1.
DR Gene3D; 2.10.25.10; Laminin; 1.
DR Gene3D; 4.10.400.10; Low-density Lipoprotein Receptor; 1.
DR Gene3D; 2.20.100.10; Thrombospondin type-1 (TSP1) repeat; 1.
DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR InterPro; IPR036055; LDL_receptor-like_sf.
DR InterPro; IPR023415; LDLR_class-A_CS.
DR InterPro; IPR002172; LDrepeatLR_classA_rpt.
DR InterPro; IPR001862; MAC_perforin.
DR InterPro; IPR020864; MACPF.
DR InterPro; IPR020863; MACPF_CS.
DR InterPro; IPR000884; TSP1_rpt.
DR InterPro; IPR036383; TSP1_rpt_sf.
DR PANTHER; PTHR45742; COMPLEMENT COMPONENT C6; 1.
DR PANTHER; PTHR45742:SF3; COMPLEMENT COMPONENT C9; 1.
DR Pfam; PF00057; Ldl_recept_a; 1.
DR Pfam; PF01823; MACPF; 1.
DR PRINTS; PR00764; COMPLEMENTC9.
DR SMART; SM00192; LDLa; 1.
DR SMART; SM00457; MACPF; 1.
DR SMART; SM00209; TSP1; 1.
DR SUPFAM; SSF57184; Growth factor receptor domain; 1.
DR SUPFAM; SSF57424; LDL receptor-like module; 1.
DR SUPFAM; SSF82895; TSP-1 type 1 repeat; 1.
DR PROSITE; PS00022; EGF_1; 1.
DR PROSITE; PS01209; LDLRA_1; 1.
DR PROSITE; PS50068; LDLRA_2; 1.
DR PROSITE; PS00279; MACPF_1; 1.
DR PROSITE; PS51412; MACPF_2; 1.
DR PROSITE; PS50092; TSP1; 1.
PE 1: Evidence at protein level;
KW Complement alternate pathway; Complement pathway; Cytolysis;
KW Disulfide bond; EGF-like domain; Glycoprotein; Immunity; Innate immunity;
KW Membrane; Membrane attack complex; Reference proteome; Secreted; Signal;
KW Target cell membrane; Target membrane; Transmembrane;
KW Transmembrane beta strand.
FT SIGNAL 1..20
FT /evidence="ECO:0000255"
FT CHAIN 21..554
FT /note="Complement component C9"
FT /id="PRO_0000023607"
FT TRANSMEM 233..240
FT /note="Beta stranded"
FT /evidence="ECO:0000250|UniProtKB:P02748"
FT TRANSMEM 267..274
FT /note="Beta stranded"
FT /evidence="ECO:0000250|UniProtKB:P02748"
FT TRANSMEM 376..383
FT /note="Beta stranded"
FT /evidence="ECO:0000250|UniProtKB:P02748"
FT TRANSMEM 384..392
FT /note="Beta stranded"
FT /evidence="ECO:0000250|UniProtKB:P02748"
FT DOMAIN 40..93
FT /note="TSP type-1"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT DOMAIN 97..134
FT /note="LDL-receptor class A"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00124"
FT DOMAIN 136..518
FT /note="MACPF"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00745"
FT DOMAIN 519..549
FT /note="EGF-like"
FT SITE 267..268
FT /note="Cleavage; by thrombin"
FT CARBOHYD 261
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 409
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 423
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT DISULFID 41..76
FT /evidence="ECO:0000250|UniProtKB:P02748"
FT DISULFID 52..86
FT /evidence="ECO:0000250|UniProtKB:P02748"
FT DISULFID 55..92
FT /evidence="ECO:0000250|UniProtKB:P02748"
FT DISULFID 99..110
FT /evidence="ECO:0000250|UniProtKB:P02748"
FT DISULFID 105..123
FT /evidence="ECO:0000250|UniProtKB:P02748"
FT DISULFID 117..132
FT /evidence="ECO:0000250|UniProtKB:P02748"
FT DISULFID 140..179
FT /evidence="ECO:0000250|UniProtKB:P02748"
FT DISULFID 382..413
FT /evidence="ECO:0000250|UniProtKB:P02748"
FT DISULFID 519..535
FT /evidence="ECO:0000250|UniProtKB:P02748"
FT DISULFID 522..537
FT /evidence="ECO:0000250|UniProtKB:P02748"
FT DISULFID 539..548
FT /evidence="ECO:0000250|UniProtKB:P02748"
FT CONFLICT 65
FT /note="I -> M (in Ref. 2; AAA96528)"
FT /evidence="ECO:0000305"
FT CONFLICT 300
FT /note="K -> R (in Ref. 2; AAA96528)"
FT /evidence="ECO:0000305"
SQ SEQUENCE 554 AA; 62281 MW; 9C885F76A1275649 CRC64;
MASGVTITLA IAIFALEINA QAPEPTPREE PSADALLPID CRMSTWSQWS QCDPCLKQRF
RSRSIEVFGQ FQGKSCADAL GDRQHCEPTQ ECEEVQENCG NDFQCETGRC IKRKLLCNGD
NDCGDFSDES DCESDPRLPC RDRVVEESEL GRTAGYGINI LGMDPLGTPF DNEFYNGLCD
RVRDGNTLTY YRKPWNVAFL AYETKADKNF RTENYEEQFE MFKTIVRDRT TSFNANLALK
FTITEAPIKK VGVDEVSPEK NSSKPKDSSV DFQFSYFKKE NFQRLSSYLS QTKKMFLHVK
GMIQLGRFVM RNRGVMLTTT FLDDVKALPV SYEKGEYFGF LETYGTHYSS SGSLGGLYEL
IYVLDKASMK EKGVELSDVK RCLGFNLDVS LYTPLQTALE GPSLTANVNH SDCLKTGDGK
VVNISRDHII DDVISFIRGG TRKQAVLLKE KLLRGAKTID VNDFINWASS LDDAPALISQ
KLSPIYNLIP LTMKDAYAKK QNMEKAIEDY VNEFSARKCY PCQNGGTAIL LDGQCMCSCT
IKFKGIACEI SKQR
//